Independent Action, Collateral Sensitivity, & Directions For Future Progress For Immune Checkpoint Inhibitors in NSCLC

Time: 8:00 am
day: Day Two


  • What is old is still true: current approved immune checkpoint inhibitor combinations depend on combinations of orthogonal cancer therapies according to principles of independent activity
  • The future is here: The emerging landscape of post-PD-1 treatment trials
  • What is old is still true: A reminder of collateral sensitivity as a historic combination principle